Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 6/20 | 0.41 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4473785 | 1.00 | EP300 (0.42) | EP300FAAHSOAT1MEN1TP53 | |
| SCHEMBL8089344 | 0.77 | GRIK1 (0.38) | EP300FAAHSOAT1MEN1TP53 | |
| SCHEMBL7529207 | 0.75 | GRIK1 (0.37) | EP300FAAHSOAT1MEN1TP53 | |
| SCHEMBL3263465 | 0.74 | CES2 (0.48) | EP300SOAT1EPHX2 | |
| SCHEMBL3263462 | 0.74 | CES2 (0.48) | EP300SOAT1EPHX2 | |
| SCHEMBL4794021 | 0.73 | CA2 (0.45) | FAAHSOAT1MEN1TP53CYP1A2 | |
| SCHEMBL5015091 | 0.71 | CA2 (0.48) | FAAHSOAT1MEN1TP53CYP1A2 | |
| SCHEMBL3217870 | 0.71 | ENPP2 (0.41) | FAAHTP53CA2ENPP2 | |
| SCHEMBL6557190 | 0.70 | EP300 (0.55) | EP300FAAHSOAT1MEN1TP53 | |
| SCHEMBL6056971 | 0.70 | EP300 (0.50) | EP300FAAHSOAT1MEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090191193-A1 | Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-07-30 | — | — | US | disclosed |
| EP-2046322-A2 | ARYL VINYL SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008016682-A2 | ARYL VINYL SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090191193-A1 | Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof | ARSA, STS, SULT2A1 | EP300 2849/4885FAAH 3560/4885SOAT1 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.